Bausch Health Companies Inc. (BHC)

Over the past six months, Bausch Health's stock has experienced several notable events. The stock gained 40% in the six months leading up to October 2025. In Q2 2025, revenue increased by 5% year-over-year to $2.53 billion, and Adjusted EBITDA rose by 5% to $871 million. The company completed a $7.9 billion debt refinancing in Q2 2025. Bausch Health provided a 2025 revenue forecast of $4.95 billion to $5.1 billion and an Adjusted EBITDA projection of $2.625 billion to $2.725 billion. In Q3 2025, Bausch Health reported consolidated revenues of $2.68 billion, a 7% increase from Q3 2024, and completed the acquisition of DURECT Corporation. In February 2026, a Phase 3 clinical trial for Xifaxan failed to support a planned label expansion, and the company's stock decreased by 15.3% year-to-date.

Specific detailed information regarding the demand seasonality for Bausch Health Cos., Inc.'s products and services is not readily available. As a diversified pharmaceutical and medical device company, demand seasonality could vary by product line and geographic region. The company's diverse product offerings and international sales may help to mitigate overall demand fluctuations.

Bausch Health Cos., Inc. is a global, diversified specialty pharmaceutical and medical device company headquartered in Laval, Quebec, Canada, operating within the Healthcare sector. The company focuses on developing, manufacturing, and marketing a broad range of therapeutic and over-the-counter offerings. Its business is structured around key segments including Ophthalmology (Bausch + Lomb), Salix, Solta Medical, Diversified Brands, and International.

Bausch Health Cos., Inc. has a global geographic footprint, operating in the United States and internationally. The company's products are sold in various regions, including Europe, the Middle East, Africa, CIS, Latin America, Canada, and Asia Pacific. Significant revenue contributions come from the U.S. and Puerto Rico, other foreign countries, China, Canada, and Poland.

Bausch Health's brand reputation in the past year has been influenced by its deleveraging efforts and the spin-off of Bausch + Lomb. The company faced and cleared bankruptcy rumors in December 2024. A Phase 3 clinical trial failure for Xifaxan in February 2026 could negatively affect the company's reputation. Despite these challenges, Bausch Health has demonstrated consistent financial performance with several consecutive quarters of year-over-year revenue and Adjusted EBITDA growth.

Institutional investors are the largest holders of Bausch Health Companies' ownership. As of early 2026, Bausch Health Companies Inc. has 284 institutional owners and shareholders holding a total of 234,869,366 shares. Key institutional owners include Paulson & Co. Inc., Goldentree Asset Management Lp, and Vanguard Group Inc. Key individual owners include John Paulson, who is the largest individual shareholder, owning 25.76% of the company's shares, and David Robert Hale and Jeffrey W. Ubben. Insiders hold a minority via equity awards.